You are here: Urology Textbook > Bladder > Bladder pain syndrome/interstitial cystitis
Bladder Pain Syndrome and Interstitial Cystitis (1/2)
- Interstitial cystitis (1/2): definition, causes, symptoms and diagnosis
- Interstitial cystitis (2/2): medical treatment and surgical therapy
Definitions of Interstitial Cystitis (IC) and Painful Bladder Syndrome (BPS)
Bladder pain syndrome (BPS)/Interstitial cystitis (IC) is disease of unknown etiology which presents with frequency, bladder pain and decreased bladder capacity (Loch and Stein, 2004). Several definitions of the disease have been formulated in the past years, the most important ones are cited:
Definition of the International Continence Society (ICS)
Bladder pain syndrome is the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night-time frequency, in the absence of proven urinary tract infection or other obvious pathology. The diagnosis interstitial cystitis is reserved to patients with typical cystoscopic and histological features (Abrams et al, 2002).
Definition of the Society for Urodynamics and Female Urology
Bladder pain syndrome or Interstitial cystitis is an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks’ duration, in the absence of infection or other identifiable causes (Hanno and Dmochowski, 2009).
Classification of interstitial cystitis:
Interstitial cystitis can be classified into classic interstitial cystitis with histological signs of inflammation and ulceration visible in cystoscopy or non-ulcer interstitial cystitis without histological signs of inflammation and without visible lesions in cystoscopy. Since the significance of the cystoscopic findings (see below) is doubted, the classification has lost its importance.
Epidemiology of the Bladder Pain Syndrome
- Prevalence is 10–500/100 000 women, depending on the inclusion criteria. Modern studies show higher prevalence rates.
- Mean age at diagnosis is 40–50 years, female to male ratio = 9:1.
Causes of Bladder Pain Syndrome and Interstitial Cystitis
The etiology of interstitial cystitis is highly controversial and most likely multifactorial. Suspected causes are discussed in the following sections. Inflammatory mast cell activation leads to increased permeability of the urothelium, fibrosis and reduction of bladder capacity.
Increased Permeability of the Urothelium:
An impaired glycosaminoglycan layer leads to a leaky urothelium and toxic substances, allergens or bacteria may invade deeper bladder wall layer and cause an inflammatory process. It is unclear whether the increased permeability of urothelium in patients with interstitial cystitis is the primary step in the pathophysiology or a consequence of an inflammatory cascade. An impaired glycosaminoglycan layer can be detected using the potassium test (see below), which is positive in a subset of patients with bladder pain syndrome. The specifity of the test is low, since the potassium test is also positive in patients with bacterial cystitis or radiation cystitis. On the other hand, there are successful treatment options which rather damage the glycosaminoglycan layer (e.g. bladder distention). Increased urothelial permeability as a primary step of IC pathophysiology remains debatable.
Infection of the Urinary Bladder Wall:
Many attempts to prove an infectious etiology for interstitial cystitis have failed. Antibiotic treatment did not prove to be effective. It is still possible that harmless organisms trigger an autoimmune reaction against components of the bladder wall. This hypothesis is supported by increased mast cells and increased concentrations of their mediators in the urothelium and bladder wall. Undisputed in the IC research anyhow is the central role of mast cells in the inflammatory cascade of interstitial cystitis. Overall, the infectious theory is seen at best as a trigger for the interstitial cystitis.
Antiproliferative Activity of the Urine:
Studies have found an antiproliferative activity in the urine of patients with interstitial cystitis. The putative factor is called antiproliferative factor (APF), which is most probable produced in the bladder and belongs the frizzled protein family. Any injury of the bladder (infection, trauma or overdistension) may lead in susceptible patients (with APF) to bladder pain syndrome or interstitial cystitis. Further studies are needed to assess the clinical significance of APF (Keay, 2008). P>
Increased stimulation of pain fibers may cause a neurogenic inflammation. Increased concentrations of mediators of neurogenic inflammation, such as substance P, neurokinin A and calcitonin gene-related protein could be detected in interstitial cystitis. The inflammatory cascade of a neurogenic inflammation is indistinguishable from a bacterial or allergic inflammation cascade. The threshold at which the bladder filling is perceived painful is significantly reduced in patients with interstitial cystitis. Recurring pain stimuli could trigger the neurogenic inflammatory cascade and maladaptive mechanisms may lead to the chronic pain syndrome.
Autoimmunity and Interstitial Cystitis:
The relationship between interstitial cystitis and autoimmunity is contradictory. It was possible to detect autoantibodies against the urinary bladder, the specificity of the laboratory findings are controversial. Secondary autoimmune phenomenons in response to inflammation are also possible. Although the non-specific inhibition of the inflammatory cascade is part of the effective therapy, the exact role of autoimmunity remains unclear.
Psychological stress and derived symptoms are interpreted as a response to the disease (voiding almost hourly and suffering from chronic pain).
Pathology of Interstitial Cystitis
The historical classification of interstitial cystitis into a classic interstitial cystitis with histological signs of inflammation and ulceration visible in cystoscopy or into a non-ulcer interstitial cystitis without histological signs of inflammation and without visible lesions has not proven to be useful. The histological signs (if any are visible) are non-specific and cannot be correlated to the clinical situation. Furthermore, even electron microscopy fails to identify any pathological correlate for interstitial cystitis. The role for pathology is to exclude other possible diseases like carcinoma in situ.
Ulcerative lesions in the bladder (Hunner ulcers) and glomerulations after bladder distention (punctate mucosal bleeding) were described to be associated with interstitial cystitis, but they be also present after e.g. radiation therapy. The sensitivity and specificity of the cystoscopic findings are controversial, they are present in only a small proportion of patients with bladder pain syndrome or interstitial cystitis. In the course of the disease, increasing fibrosis of the bladder wall leads to a diminished bladder capacity.
Mast cell infiltration of the bladder wall, infiltrates of lymphocytes, ulcerative defects of the urothelium, small subepithelial hemorrhages. The histological signs (if any are visible) are non-specific and cannot be correlated to the clinical situation.
Signs and Symptoms of Bladder Pain Syndrome and Interstitial Cystitis
- Pain, pressure or discomfort perceived to be related to the bladder
- At least one other urinary symptom: frequency, nocturia or urgency
- Duration of symptoms for at least 6 weeks without any explanatory etiology
Due to the varying intensity, several symptom scores were created to monitor the therapeutic effect: IC symptom index (ICSI) and IC Problem Index (ICPI), University of Wisconsin IC Scale (UW-IC Scale).
Diagnosis of Bladder Pain Syndrome and Interstitial Cystitis
Prerequisite for diagnosis "bladder pain syndrome" or "interstitial cystitis" are above mentioned basic symptoms without any explanatory etiology. Crucial for the diagnosis is the exclusion of the long list of differential diagnosis, see differential diagnosis .
A micturition protocol is useful to assess frequency and voided volumes. Voided volumes of less than 250 ml, micturition at least every two hours and always nocturia are typical for interstitial cystitis.
- Urine sediment and urine culture to exclude urinary tract infection
- Urine cytology: to exclude bladder cancer (especially carcinoma in situ).
Ultrasound imaging is done to exclude kidney and bladder diseases.
In patients with bladder pain syndrome, cystoscopy should be performed under general anesthesia. The bladder is distended under vision with a pressure of 80–100 cm H2O for 2 min, a measurement of the bladder capacity is done. After re-filling the bladder is inspected for glomerulations, Hunner ulcers and for differential diagnosis. The sensitivity and specificity of the cystoscopic findings are controversial (see above). A quadrant biopsy of the bladder is done to exclude bladder cancer (carcinoma in situ).
Potassium Chloride Test:
Intravesical KCl (0.4 M) produces pain in a subset of patients with bladder pain syndrome. The potassium chloride test claims to indicate abnormal epithelial permeability. Clinical studies failed to prove any benefit in the management of patients with bladder pain syndrome and interstitial cystitis, since the sensitivity and specifity is very low.
Urodynamic studies are useful in unclear cases with bladder pain syndrome, especially to exclude an overactive bladder. Cystometry usually reveals pain on bladder filling and a normal detrusor function.
Differential diagnosis of the Bladder Pain Syndrome
- Infections: acute cystitis, schistosomiasis, urogenital tuberculosis
- Neurological diseases with bladder symptoms
- Diseases of the prostate: bacterial prostatitis, prostate cancer
- Bladder stones
- Bladder cancer, especially carcinoma in situ of the urinary bladder
- Gynecological diseases: estrogen deficiency, endometriosis, infections (vaginitis, salpingitis), cancer of the cervix, ovary or endometrium.
- Radiation therapy of pelvic organs
- Side effects of drugs like cyclophosphamide
|Bladder stones||Index||IC therapy|
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.;
Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. & of
the International Continence Society, S. S.
- The standardisation of
terminology of lower urinary tract function: report from the
Standardisation Sub-committee of the International Continence Society.
Neurourol Urodyn, 2002, 21, 167–178.
- Hanno, P. & Dmochowski, R.
- Status of international consensus on interstitial cystitis/bladder pain
syndrome/painful bladder syndrome: 2008 snapshot.
Neurourol Urodyn, 2009, 28, 274-286.
- von Heyden 2000 HEYDEN, B. von:
- Intravesikale Therapie bei interstitielle Zystitis.
In: Urologe A
39 (2000), S. 542–544
- Keay, S.
- Cell signaling in interstitial
cystitis/painful bladder syndrome.
Cell Signal, 2008, 20, 2174-2179.
- Loch, A. & Stein, U.
- [Interstitial cystitis. Current aspects of diagnosis and therapy].
Urologe A, 2004, 43, 1135-1146.
- Oberpenning u.a. 2000 OBERPENNING, F. ; OPHOVEN, A. van ; HERWIG, R. ; PIECHOTA, H. J.:
- [Diagnosis of interstitial cystitis].
In: Urologe A
39 (2000), Nr. 6, S. 530–4
- Sievert u.a. 2000 SIEVERT, K. D. ; EDENFELD, K. D. ; OBERPENNING, F. ; PIECHOTA, H. J.:
- [Oral therapy of interstitial cystitis].
In: Urologe A
39 (2000), Nr. 6, S. 535–8
Deutsche Version: Interstitielle Zystitis